Potential Clinical Implications of miR-1 and miR-21 in Heart Disease and Cardioprotection

Int J Mol Sci. 2020 Jan 21;21(3):700. doi: 10.3390/ijms21030700.

Abstract

The interest in non-coding RNAs, which started more than a decade ago, has still not weakened. A wealth of experimental and clinical studies has suggested the potential of non-coding RNAs, especially the short-sized microRNAs (miRs), to be used as the new generation of therapeutic targets and biomarkers of cardiovascular disease, an ever-growing public health issue in the modern world. Among the hundreds of miRs characterized so far, microRNA-1 (miR-1) and microRNA-21 (miR-21) have received some attention and have been associated with cardiac injury and cardioprotection. In this review article, we summarize the current knowledge of the function of these two miRs in the heart, their association with cardiac injury, and their potential cardioprotective roles and biomarker value. While this field has already been extensively studied, much remains to be done before research findings can be translated into clinical application for patient's benefit.

Keywords: biomarkers; cardioprotection; cardiovascular diseases; microRNA-1 (miR-1); microRNA-21 (miR-21).

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / toxicity
  • Arrhythmias, Cardiac / drug therapy
  • Biomarkers
  • Cardiomyopathies / drug therapy
  • Cardiotonic Agents / therapeutic use*
  • Cardiotoxins
  • Cardiovascular Diseases / drug therapy
  • Heart
  • Heart Diseases / chemically induced
  • Heart Diseases / drug therapy*
  • Heart Injuries / chemically induced
  • Heart Injuries / drug therapy
  • Humans
  • MicroRNAs / therapeutic use*
  • Radiotherapy / adverse effects

Substances

  • Antineoplastic Agents
  • Biomarkers
  • Cardiotonic Agents
  • Cardiotoxins
  • MIRN1 microRNA, human
  • MIRN21 microRNA, human
  • MicroRNAs